VIVO Cannabis has published a medical cannabis clinical research study exploring anxiety and depression outcomes in medical cannabis patients.
VIVO Cannabis, a Canadian provider of medical cannabis products and patient services has announced results from its first study investigating how medical cannabis impacts anxiety and depression outcomes.
The publication, entitled “Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study” was published in the peer-reviewed journal Psychiatry Research and was completed by VIVO’s Harvest Medicine Inc (HMED) subsidiary.
According to the company, it is the largest study to date of its kind. The project examines the impact of medical cannabis using longitudinal data and completed validated questionnaires for anxiety and depression in 7,362 Canadian patients. Analyses were conducted for three different time points: three-six months, 12-18 months and 24 months or greater.
The study was led by HMED’s team of prescribing clinicians and physician support staff. Patients using medical cannabis for anxiety and/or depression saw statistically significant improved outcomes between baseline and follow-up scores. Results from the study are positive, providing evidence to support the effectiveness of medical cannabis as a treatment for anxiety and depression.
“Since 2017, Harvest Medicine has been an industry-leading, high volume cannabis clinic network, and our team has worked hard to share these clinical insights in an effort to contribute to the medical cannabis literature and to reduce stigma amongst health care professionals,” said Carole Chan, RPh, President of Harvest Medicine. “We are committed to further research and advancing patient outcomes with an evidence-informed approach to patient care.”
Through its Canna Farms and ABcann business units, VIVO holds production and sales licences from Health Canada and operates indoor cultivation facilities across the country. Through its network of medical cannabis clinics, the company has serviced over 200,000 patient visits. The company is currently pursuing partnership and product development opportunities and is focusing its international efforts on Germany and Australia.
